Physician profile

Ioannis Mantzaris

Bronx, NY

NPI 1871865519

$3,407.22

in general payments reported to CMS, 2019-2025

25 companies · $596 in 2025

The $596 reported for 2025 was more than what 82% of providers received nationally.

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$721.39
Education$43.25

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Kite Pharma, INC. $2,947.46 2022-2025 Yescarta
Abbvie INC. $99.12 2023-2025
Janssen Biotech, INC. $74.58 2019-2025 Tecvayli, Darzalex, Talvey
Pfizer INC. $57.38 2019-2025
Sanofi-Aventis U.S. LLC $49.36 2024-2025
Astrazeneca Pharmaceuticals LP $43.25 2025 Enhertu
Acrotech Biopharma INC. $37.13 2025 Beleodaq
Merck Sharp & Dohme LLC $24.46 2025 Keytruda Qlex, Keytruda
Astellas Pharma US INC $20.08 2022
Genentech USA, INC. $16.29 2019
Spectrum Pharmaceuticals INC. $15.66 2019
Genzyme Corporation $11.38 2020
Pharmacyclics LLC, An Abbvie Company $11.07 2019

12 companies reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$2,886.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Ioannis Mantzaris

$3,407.22

in general payments reported 2019-2025

Years
2019-2025
Top company
Kite Pharma, INC.
Context
The $596 reported for 2025 was more than what 82% of providers received nationally.

https://glasscript.com/doctor/1388282/ioannis-mantzaris

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.